SEQ

Diciembre 2016, Vol. 29(Suppl. 2): 1-31 PDF Imprimir E-mail

Revista Española de Quimioterapia

Diciembre 2016; Vol. 29 (Suppl. nº 2)

© 2016 Sociedad Española de Quimioterapia

      NÚMERO COMPLETO
                                               REQ29sup2

Índice

• Presentación

Veinte años de anfotericina B liposomal en la historia del tratamiento antifúngico en España      
CARLOS VALLEJO                                                                                        
Rev Esp Quimioter 2016;29(Suppl. 2):1-2 [pdf]

 
• Artículos comentados
 
 
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. Walsh JT, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 2002; 346:225-34.
LOURDES VÁZQUEZ
Rev Esp Quimioter 2016;29(Suppl. 2):3-5 [pdf]
 
Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. Bellmann R, Egger P, Gritsch W, Bellmann-Weiler R, Joannidis M, Kaneider N, Dunzendorfer S, Wiedermann CJ. J Antimicrob Chemother 2003; 51: 671-681
JOSÉ PERAL GUTIERREZ DE CEBALLOS
Rev Esp Quimioter 2016;29(Suppl. 2):6-8 [pdf]
 
Voriconazole versus amphotericin B in cancer patients with neutropenia. Jorgensen KJ, Gotzsche PC, Johansen HK. The Cochrane Database Systematic Reviews 2006, Issue 1. Art. No: CD004707.
ISABEL RUIZ CAMPS 
Rev Esp Quimioter 2016;29(Suppl. 2):9-12 [pdf]
 
Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High–Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E et al. Clinical Infectious Diseases 2007; 44:1289–97.
JESÚS FORTÚN ABETE 
Rev Esp Quimioter 2016;29(Suppl. 2):13-16 [pdf]
 
Impact of the Administration of Liposomal Amphotericin B in Patients with Renal Function Impairment at Initiation of Treatment. Álvarez-Lerma F, Mariscal F, Quintana E, Rialp G, Díaz Regañón J, Pérez San José MJ, Álvarez Sánchez B and The Liposomal amphotericin B in the ICU study group. J Chemother 2010; 22:285-7.
FRANCISCO ÁLVAREZ-LERMA, ROSANA MUÑOZ-BERMUDEZ 
Rev Esp Quimioter 2016;29(Suppl. 2):17-19 [pdf]
 
Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC⁄MSG 2008 definitions of invasive mould disease. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Dellow E, Herbrecht R et al. Mycoses 2011;54(5):e449-55.
CELIA CARDOZO, CAROLINA GARCÍA-VIDAL 
Rev Esp Quimioter 2016;29(Suppl. 2):20-22 [pdf]
 
Recommendations for the treatment of invasive fungal infection caused by filamentous fungi in the hematological patient. Barberán J, Mensa J, Vallejo Llamas JC, Jarque Ramos I, García Ruiz JC, Cabrera Marín JR et al. Rev Esp Quimioter 2011; 24:263-70.
JOSÉ BARBERÁN, JOSÉ MENSA 
Rev Esp Quimioter 2016;29(Suppl. 2):23-25 [pdf]
 
Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles. De la Serna J, Jarque I, Lopez-Jimenez J, Fernández Navarro JM, Gómez V, Jurado M et al. Rev Esp Quimioter 2013; 26:64-9.
JAIME PÉREZ DE OTEYZA 
Rev Esp Quimioter 2016;29(Suppl. 2):26-27 [pdf]
 
Epidemiology, diagnosis and treatment of fungal respiratory infection in the critically ill patients. Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, Alvarez-Rocha L, Blanquer J, Galván B et al. Rev Esp Quimiter 2013; 26: 173-88.
PEDRO M OLAECHEA ASTIGARRAGA 
Rev Esp Quimioter 2016;29(Suppl. 2):28-31 [pdf]
 
 
 

 • Instrucciones a los autores [pdf]